GO
Loading...

Elan Corporation PLC

More

  • Wyeth & Elan Are Real Hot Topic At Investor Meeting Thursday, 12 Jun 2008 | 3:18 PM ET

    I'm at the Needham & Company biotech conference in New York City. Whenever possible I like to attend events like this. It's a good place to get story ideas. The Needham meeting is competing this year with a similar one being put on by Goldman Sachs in Laguna Beach, CA.

  • Wyeth and Elan Face Big Test Wednesday, 11 Jun 2008 | 12:29 PM ET
    Wyeth

    Cancer, diabetes and Alzheimer's Disease. Three of the biggest areas of unmet medical need have been or will be in focus at a series of important scientific meetings in June or July.

  • Biotech’s Biggest Weekend Wednesday, 28 May 2008 | 6:27 PM ET

    With the ASCO conference beginning Friday new cancer drugs are likely to grab headlines. How should you trade ahead of biotech’s biggest weekend?

  • 4-Star Biotech Stocks Wednesday, 14 May 2008 | 12:03 PM ET

    Will Muggia likes biotech. He's co-portfolio manager of the Touchstone Mid-Cap Growth Fund, which is up an average of 14.9 percent annually over the last three years -- and even this year, it's up 1.8 percent. So what are the 4-star portfolio manager's picks?

  • Pops & Drops: American Airlines, Movado... Wednesday, 16 Apr 2008 | 6:31 PM ET

    Following are the day’s biggest winners and losers. Find out why shares of AMR Corp. and Movado popped while Sallie Mae and Safeway dropped.

  • Alzheimer's Miracle? Monday, 7 Apr 2008 | 6:33 PM ET

    Shares of Wyeth and Elan surged Monday on the promise of a new Alzheimer's drug. Can you trade it?

  • Schering-Plough And The Vytorin-Zetia Backstory Monday, 7 Apr 2008 | 11:31 AM ET

    The Star-Ledger of New Jersey this weekend did a story that I think provides the best insight and backstory about what happened last week at the highest levels of Schering-Plough.CEO Fred Hassan was in Miami when doctors dropped the bomb on Vytorin and Zetia at the American College of Cardiology meeting.

  • Ten Million Baby Boomers May Get Alzheimer's Tuesday, 18 Mar 2008 | 1:19 AM ET

    An estimated 10 million baby boomers -- or one out of eight -- will get Alzheimer's Disease according to a new report from the Alzheimer's Association.

  • Baxter, Biogen Idec & Elan Subjects of Broken Embargoes Wednesday, 5 Mar 2008 | 8:15 AM ET

    Embargoes imposed by scientific groups and medical journals will once again be put to the test over the next couple of months.

  • Waiting For FDA--In the Meantime, Your Emails Friday, 22 Feb 2008 | 12:03 PM ET

    As we sit here closely monitoring the wires and waiting for word out of Genentech and/or the FDA about a decision on Avastin for breast cancer, it seemed like as good a time as any to once again post some samples of a flood of recent emails from readers--the good, the bad and the ugly.

  • Lightning Round: Elan, Ford, Textron and More Wednesday, 6 Feb 2008 | 6:43 PM ET

    Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Biogen Idec Draws "Line In The Sand" With Carl Icahn Wednesday, 6 Feb 2008 | 11:28 AM ET

    I'm blogging a little later than usual because I got sidetracked by the breaking news on the government stopping part of a big diabetes drug study over safety concerns--more people died in a group that was being intensively treated to get their blood sugar levels below current recommendations.

  • Drug from Biogen Idec, Elan Gets FDA Approval Monday, 14 Jan 2008 | 3:52 PM ET

    Biogen Idec and Elan Corp. have won U.S. approval to market the drug Tysabri for treating the bowel disorder Crohn's disease, U.S. regulators said on Monday.

  • DNA's Test Thursday, 10 Jan 2008 | 7:21 PM ET

    Genentech kicks off biotech earnings season Monday after the bell. Will higher sales of Avastin and Herceptin drive shares?

  • Fourth quarter earnings season begins in earnest this week. On Friday, the weak jobs report forced traders to question the recent overweight in tech, industrials and materials. This overweight was based on the assumption that: 1) the U.S. was unlikely to be entering a serious slowdown.

  • Novartis Cuts, While Biogen Idec Cuts And Runs Thursday, 13 Dec 2007 | 4:06 PM ET
    Novartis

    Novartis is the latest company to brand its downsizing, cost-cutting campaign. The Swiss drugmaker is calling its initiative, "Forward". It's not an acronym. So, "Forward" means Novartis is going to try to save $1.6 billion in 2010 and get rid of 2,500 employees. Although I don't think "Forward" is the word which begins with "f" that the affected workers would use to describe the initiative.

  • Lightning Round: Akamai, Elan and Under Armour Wednesday, 28 Nov 2007 | 11:13 AM ET

    Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Alzheimer's Blood Test: Would You Take It? Monday, 15 Oct 2007 | 1:52 PM ET
    Cat scan image of human brain

    This morning on "Squawk Box" and "Squawk on the Street" I reported on a new study showing that a simple blood test might predict whether you will develop Alzheimer's Disease. The report, which appears in the scientific, peer-reviewed journal "Nature Medicine...

  • Biogen Expected to Fetch up to $30 Billion Monday, 15 Oct 2007 | 10:11 AM ET

    Biogen Idec, which has put itself up for sale, may get bids of around $25-30 billion from several of the world's top drugmakers keen to expand in the hot area of biotech medicine.

  • Biogen Idec Says It Is Seeking Takeover Bids Friday, 12 Oct 2007 | 5:38 PM ET

    Biogen Idec, which makes the multiple sclerosis drugs Avonex and Tysabri, said onFriday that it has put itself up for sale.

Most Popular Video

Wednesday, 16 Apr 2014 | 6:00 PM ET

Mad Money host Jim Cramer dissects earnings this quarter thus far and explains why be believes companies are part of the solution and not the problem in this market.

Wednesday, 16 Apr 2014 | 10:41 AM ET

CNBC's Dominic Chu digs into the year-to-date S&P performance of the airlines and explains why it has been the lone bright spot for the industrial sector.

Wednesday, 16 Apr 2014 | 4:03 PM ET

Providing instant analysis to Google's quarterly numbers, with Victor Anthony, Topeka Capital Markets; Andrew Stoltmann of Stoltmann Law Offices; CNBC contributor Michael Yoshikami; "Fast Money" trader Tim Seymour; CNBC's Michelle Caruso-Cabrera and Dominic Chu.